Skip to main content
ABIONYX Pharma logo

ABIONYX Pharma — Investor Relations & Filings

Ticker · ABNX ISIN · FR0012616852 LEI · 969500785J7VIC5YPC96 PA Manufacturing
Open in API
Filings indexed 665 across all filing types
Latest filing 2026-06-09 AGM Information
Country FR France
Listing PA ABNX

About ABIONYX Pharma

https://abionyx.com/en/

ABIONYX Pharma is a new-generation biotechnology company that develops innovative therapies for indications with no effective or existing treatments. The company leverages extensive expertise in lipid metabolism and is a leader in recombinant apolipoprotein A-I (apoA-I), the primary protein of High-Density Lipoprotein (HDL). Its core technology platform utilizes apoA-I to create novel biotherapies and HDL vectors for targeted drug delivery. Key therapeutic areas of focus include critical illnesses such as sepsis, as well as renal and ophthalmological diseases. The company's strategy involves an integrated approach, combining biotherapy with diagnostics to address complex medical conditions with high unmet needs.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
AGM Information Classification · 75% confidence The document is a corporate press release announcing the date, access to preparatory materials, and voting procedures for the Combined Annual General Meeting. It does not include financial results, proxy statements, or legal disclosures, nor does it publish a report; rather it provides information around the AGM and how to participate. This aligns with the AGM Information category.
2026-06-09 English
Informations privilégiées / Autres communiqués
Proxy Solicitation & Information Statement Classification · 87% confidence The document is a press release announcing the convening of a mixed Annual General Meeting on June 30, 2026, and notifying shareholders that the preparatory proxy materials (“documents préparatoires”) are available along with voting procedures. It is not the AGM materials themselves nor a financial report but rather an announcement to solicit proxies and inform shareholders how to participate and vote. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2026-06-09 French
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 84% confidence The document is a monthly statement of total voting rights and shares forming the company’s share capital, issued under French Commercial Code and AMF regulations. This fits the definition of “Declaration of Voting Results & Voting Rights Announcements” rather than a full financial report or a major shareholding notification.
2026-06-02 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 72% confidence The document is a press release providing the total number of shares outstanding and voting rights for ABIONYX Pharma as of a specific date, with no indication of share issuance, voting results from a meeting, or a major shareholder crossing thresholds. It is a routine regulatory announcement of share capital and voting rights rather than a financial report, AGM material, proxy solicitation, or threshold notification. It therefore falls into the miscellaneous regulatory filings category.
2026-06-02 French
Inside Information / Other news releases
Earnings Release Classification · 90% confidence The document is a press release providing key highlights of the company’s first quarter 2026 financial performance (revenue, cash position) and upcoming capital increase. It is not a full interim report with complete financial statements but rather an initial quarterly results announcement. This matches the definition of an Earnings Release (ER). Q1 2026
2026-05-28 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 85% confidence The document is a press‐release (“Communiqué de presse”) announcing Q1 2026 operational and financial highlights (revenue, cash position and secured funding) with a small IFRS table. It is not a full interim report but an earnings update summarizing quarterly results, fitting the Earnings Release definition. Q1 2026
2026-05-28 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.